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Pyridine-3-carboxamide, also known as niacinamide (NIA), is used in many 
pharmaceutical and personal care formulations for the improvement of skin barrier function, 
management of acne and amelioration of the symptoms of atopic dermatitis [1-3]. The 
widespread use of NIA (Table I) in skin care highlights the importance of understanding the 
percutaneous penetration and skin distribution of this molecule [4]. Previously, we have 
conducted several studies that have evaluated a wide variety of NIA formulations [4, 5]. The 
amounts of NIA recovered in mass balance studies for pseudo-finite (20 µL/cm
2
) and finite (5 
µL/cm
2
) dose conditions fell below the Scientific Committee on Consumer Safety (SCCS) 
limits for dermal absorption studies (85–115%) [6]. The aim of the present work was to 
explore and identify the possible formation of molecular derivatives of NIA during dermal 
penetration experiments that may explain the previously reported recovery values. The major 
metabolites of NIA include niacin, nicotinuric acid and niacinamide N-oxide however none 
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of these species could be identified in our previous investigations [7]. The present approach 
focusses on the detection and isolation of other liquid chromatography (LC) peaks that did 
not correlate to the known metabolites of NIA. The identification of such peaks using liquid 
chromatography mass-spectrometry (LC-MS) should thereby address the reasons for the 
lower recovery values of NIA in our earlier studies and ideally facilitate the development of 
more sensitive analytical methods to measure NIA following topical application.  
NIA was purchased from Sigma Aldrich, UK. Commercial formulations used 
contained glycerin, niacinamide, 2-methylpentadecane, dimethicone, isopropyl isodecanoate, 
stearyl alcohol, panthenol, tocopheryl acetate, 1-hexadecanol, polyacrylamide, behenyl 
alcohol, titanium dioxide, C13-14 isoparaffin, 1,2-octanediol, hexamethylene glycol, 
phenoxyethanol, dimethylsilanediol, dodecylheptaglycol, sodium benzoate, sodium ascorbyl 
phosphate, peg-100 stearate, cetearyl glucoside, cetearyl alcohol, disodium EDTA, stearic 
acid, palmitic acid, butylated hydroxytoluene, zinc oxide and triethoxycaprylylsilane. All 
non-commercial formulations contained hydrogenated lecithin, capric caprylic triglyceride, 
isoamyl p-methoxycinnamate, diethylamino hydroxybenzoyl hexyl benzoate, bis-
ethylhexylphenol methoxyphenyl triazine, shea butter, glycerine, olus oil, isostearyl 
isostearate, dicapryl carbonate, xylitol, panthenol, niacinamide, pentylene glycol and 1,2-
hexanediol. All formulations were supplied by Glaxo Smith Kline (GSK, UK). LC-MS grade 
water, methanol and dichloromethane (DCM) were obtained from Fisher Scientific, UK. 
Phosphate buffer saline (PBS) tablets were purchased from Oxoid Limited, England. Porcine 
tissue was obtained from a local abattoir and kept at -20 °C until usage. 
Studies of NIA in Franz diffusion cells were conducted using different doses (50 µL 
/cm
2
 and 20 µL/cm
2
) of formulations applied to full thickness porcine ear skin. Skin integrity 
was confirmed by evaluation of electrical resistance. Freshly prepared PBS (pH 7.3 ± 0.1) 
was used as the receptor solution in all studies. The skin temperature was equilibrated to 32 ± 
1 °C and formulations were applied using an Eppendorf® Multipette Plus (Merck, UK). The 
donor compartment was occluded using Parafilm® after application of the formulations. A 
sample of 200 µL of receptor solution was removed from the receptor compartment at 
various time intervals up to 24 hours, with aliquot replacement using fresh temperature 
equilibrated PBS solution [5, 8]. Samples were analysed by LC and all unassigned peaks are 
shown in Fig.1. After the 24 hours, the PBS solution in the receptor compartment of the 
Franz diffusion cell was collected for further extraction. Two different approaches were 
devised to isolate any previous unassigned NIA related LC peaks, categorised as organic and 
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inorganic routes. The organic route involved the partitioning of different NIA by-products 
between a PBS:DCM mixture. The aqueous layer was extracted three times using 5 mL of 
DCM. After evaporation of the organic solvent, the residue was dissolved in a 
water:methanol (50:50) mixture and analysed by LC-MS. The inorganic route involved freeze 
drying the 24 hours PBS sample. The extraction of potential NIA by-products from the dry 
residue was carried out with 100 µL of a water:methanol (50:50) mixture. Following sample 
extraction and filtration of undissolved residue, semi-preparative LC was performed. This 
was followed by LC-MS analysis of all previous unassigned peaks including that for NIA. 
The analysis of NIA and NIA by-products was conducted using an Agilent Infinity II 
1260 (Agilent Technologies, UK) system equipped with an Agilent G7129A vial sampler, 
G7111B quaternary pump and G7114A variable wavelength detector coupled to a single 
quadrupole mass spectrometer Agilent Infinity Lab LC-MSD XT. The mass spectrometer was 
set at positive ion mode operation at 350 °C and with an ion spray voltage set to 10000 V. 
Zero air was employed as the nebulizer gas and heater gas, with nitrogen used as the curtain 
gas (35 psi) and collision gas. Data were processed using OpenLab CDS ChemStation 
software (Agilent Technologies, UK). Analysis was performed using a Phenomenex Luna 
Phenyl Hexyl column (Phenomenex, UK) with a length, internal diameter and particle size of 
250 mm, 4.6 mm and 5 µm, respectively and a guard column. The mobile phase consisted of 
water:methanol (80:20). The pH of the mobile phase (7.4) was not adjusted to prevent 
possible chemical conversions of any NIA by-products formed during the permeation studies. 
The mobile phase was degassed using an ultrasonicator (VWR International) prior to use to 
remove air bubbles. The flow rate of the mobile phase was 1 mL/min and the column 
temperature was maintained at 40 °C. Chromatograms were acquired at a wavelength of 263 
nm. Sample volumes of 100 µL (for semi-preparative LC) and 10 µL (for analytical LC-MS) 
were injected for a total run time of 10 min. Samples were lyophilised using a Thermo 
Scientific Heto Powerdry LL1500 manifold freeze dryer equipped with a RC 6 chemistry-
HYBRID rotary high vacuum pump (Vacuubrand®, UK), with the condenser temperature set 
at -113 °C. 
Isolation of NIA related by-products using the organic route was not successful as no 
significant LC-MS trace signals were found following sample separation and 
characterisation. This could have been the result of an extended PBS environmental exposure 
that led to possible salt formation of NIA and other more polar related structures. However, 
compound isolation using the inorganic route resulted in the appearance of two LC peaks 
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which were categorised based on run retention times as NIA and a more polar unknown 
compound (Fig. 2). Subsequent preparative LC separation was conducted and LC-MS 
analysis of these two isolates demonstrated the existence of NIA: m/z 123 for NIA+H and 
145 for NIA+Na (Fig. 2, D1 and D2); in addition to the presence of unknown NIA by-
products (Fig. 2, E1 and E2). 
Following analysis and characterisation of the mass spectrometry data, an additional 
molecular structure was confirmed in the porcine skin permeation samples and was identified 
as 1,4,5,6-tetrahydropyridine-3-carboxamide (Fig. 3, compound 3) [9]. With an m/z of 126 
(m/z 127 for M+H, Fig. 4), this molecular entity is thought to be a product of the chemical 
reduction of NIA as it permeates through porcine skin. This conclusion is supported by the 
highest ion abundance shown in Fig. 4 (i.e. m/z 173) which indicates the presence of this 
same molecule as its ion adduct for M+H+2Na. The presence of a m/z 149 value (Fig. 4) also 
correlates with the presence of the M+Na ion adduct for 1,4,5,6-tetrahydropyridine-3-
carboxamide, confirming the existence of this NIA by-product. Moreover, the minor increase 
in polarity of this compound compared to NIA is shown by its lower LC run retention time. 
Results also showed an m/z 151 value (Fig. 4) which may reflect the presence of piperidine-3-
carboxamide (Fig.3, compound 4) for M+Na in addition to an m/z 171 value (Fig. 4) that 
suggests the existence of 1,4-dihydropyridine-3-carboxamide (Fig. 3, compound 2) for 
M+H+2Na. 
To confirm that these species were uncharacterised ion adducts of NIA by-products, 
skin permeation experiments and the same LC-MS analysis was conducted with control 
formulations with no NIA. Analysis of NIA in PBS alone was also conducted to evaluate 
possible chemical derivatisation of the compound in the Franz diffusion cell receptor 
compartment. However, none of the molecular structures reported in Fig. 4 could be detected 
following these experiments. 
Lo and Sajiki previously reported the chemical reduction of the pyridine ring in NIA 
as well as NIA structural analogues [9, 10]. Our findings are consistent with these authors, 
namely the presence of a number of compounds following the reduction of NIA. The results 
further suggest that the low recovery of NIA following skin penetration and mass balance 
studies reflects chemical derivatisation of the molecule during skin penetration. The next 
steps of the work will be to synthesise the NIA by-products by reduction of NIA to facilitate 
further LC-MS molecular classification and quantification of relevant NIA derivatives. This 
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should enable the development of more sensitive methods to ensure full mass balance 
recovery of NIA following skin application. 
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Table I – Physicochemical properties of niacinamide (NIA) 
 
Molecular structure 
 
Molecular weight 122.13 Da [11] 
m/z 122.05 (100.0%), 123.05 (6.5%) [11, 12] 
Log P (o/w) -0.37 [13] 
pKa 3.35 [14] 
Solubility 
1 g dissolves in about 1 mL water, in 10 
mL glycerol, in about 1.5 mL alcohol [15] 
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Figure 1 – NIA permeation study LC spectrums at different timepoints. From top to bottom: A - 2 hours; B - 12 hours; C - 
24 hours 
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D1 D2 
E1 E2 
Figure 2 – NIA and unknown compound LC-MS spectrums. Top: D1 – NIA LC spectrum and D2 – NIA MS spectrum; bottom: E1 – Unknown compound LC spectrum and E2 – Unknown compound MS 
spectrum 
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Figure 3 – Proposed NIA reduction pathway for the formation of its by-products 
 
 
 
 
 
 
 
Figure 4 – Unknown NIA by-products MS spectrum 
 
 
 
 
 
 
